17th Sep 2014 09:31
LONDON (Alliance News) - OptiBiotix Health PLC said Wednesday it has signed a deal with Netherlands-based contract food research group, Nizo Food Research BV.
The life sciences company, which develops compounds to tackle obesity, high cholesterol and diabetes, has given the contract to Nizo to work on pre-claims support for three cholesterol-lower Lactobacillus strains developed by OptiBiotix in the past two years.
The strains have shown an ability to cut cholesterol by between 72% and 81% in laboratory studies, OptiBiotix said.
Nizo will work on assessing the manufacturability of each strain, with a view to determining the best strain to enter human studies for its first product, a capsular food supplement scheduled for 2015.
"Pre-clinical claims support is an important milestone in determining which of our three cholesterol reducing Lactobacillus strains is best suited for our first product, and is most likely to lead to a successful outcome in human studies," said OptiBiotix Chief Executive Stephen O'Hara.
"We expect this work to be completed by the end of 2014 so we can commence human studies in early 2015," O'Hara said.
OptiBiotix shares were up 0.3% to 9.275 pence per share on Wednesday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
OptiBiotix Health